HUP0100397A2 - Tetrahidro- vagy oktahidrobenzo-naftiridin és kinolinszármazékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra - Google Patents
Tetrahidro- vagy oktahidrobenzo-naftiridin és kinolinszármazékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukraInfo
- Publication number
- HUP0100397A2 HUP0100397A2 HU0100397A HUP0100397A HUP0100397A2 HU P0100397 A2 HUP0100397 A2 HU P0100397A2 HU 0100397 A HU0100397 A HU 0100397A HU P0100397 A HUP0100397 A HU P0100397A HU P0100397 A2 HUP0100397 A2 HU P0100397A2
- Authority
- HU
- Hungary
- Prior art keywords
- group
- optionally substituted
- general formula
- optionally
- aromatic
- Prior art date
Links
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical class N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 2
- 125000004122 cyclic group Chemical group 0.000 abstract 2
- 125000005842 heteroatom Chemical group 0.000 abstract 2
- 125000001183 hydrocarbyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 229910052760 oxygen Inorganic materials 0.000 abstract 2
- 239000001301 oxygen Substances 0.000 abstract 2
- 229920006395 saturated elastomer Polymers 0.000 abstract 2
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 208000006386 Bone Resorption Diseases 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 206010027476 Metastases Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 206010047139 Vasoconstriction Diseases 0.000 abstract 1
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000304 alkynyl group Chemical group 0.000 abstract 1
- 230000033115 angiogenesis Effects 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 1
- 230000024279 bone resorption Effects 0.000 abstract 1
- 125000005843 halogen group Chemical group 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000009401 metastasis Effects 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 125000003367 polycyclic group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229930195734 saturated hydrocarbon Natural products 0.000 abstract 1
- -1 substituted Chemical class 0.000 abstract 1
- 125000000547 substituted alkyl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 230000004614 tumor growth Effects 0.000 abstract 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 abstract 1
- 230000025033 vasoconstriction Effects 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
- 230000029663 wound healing Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/55—Acids; Esters
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
Abstract
A találmány tárgyát (B) általános képletű vegyületek és sóik, ezekettartalmazó gyógyszerkészítmények és ezek előállítása képezi.Közelebbről, a találmány szerinti vegyületek az av<3, az av<5 és/vagyav<6 integrin receptorok antagonistái, és csontfelszívódás gátlásában,oszteoporózis kezelésére vagy megelőzésére, ér-újrabeszűkülés,diabéteszes retinopátia, makuladegenerálódás, angingenezis,ateroszklerózis, gyulladások, vírusfertőzések, tumornövekedés és -áttét gátlására és sebgyógyulás kezelésére alkalmazhatók. A találmányszerinti vegyületek (B) általános képletében X jelentése (1) általánosképletű csoport, 5- vagy 6-tagú monociklusos aromás vagy nem-aromás,adott esetben heteroatomot tartalmazó és adott esetben helyettesítettgyűrűrendszer, vagy 9-14-tagú policiklusos, adott esetben heteroatomottartalmazó és adott esetben helyettesített gyűrűrendszer, amelyben agyűrűk közül egy vagy több aromás; Y jelentése adott esetben egy vagytöbb oxigén, nitrogén és/vagy kén heteroatomot tartalmazó, adottesetben helyettesített telített lineáris szénhidrogénlánc; Z jelentése(3), (4) vagy (5) általános képletű csoport, vagy adott esetbenhelyettesített -CH2CH2- vagy -CH=CH- csoport; R5, R6, R7 és R8jelentése egymástól függetlenül többek között hidrogénatom, alkil-vagy arilcsoport, halogénatom, hidroxilcsoport, alkenil- vagyalkinilcsoport, adott esetben oxigén-, nitrogén- és/vagy kénatomottartalmazó, adott esetben helyettesített telített vagy telítetlenszénhidrogénlánc, és további helyettesített amino- és alkilcsoportok;R9 jelentése hidrogénatom, arilcsoport vagy adott esetbenhelyettesített alkil-csoport. Ó
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6989997P | 1997-12-17 | 1997-12-17 | |
GBGB9807382.8A GB9807382D0 (en) | 1998-04-06 | 1998-04-06 | Vitronectin receptor antagonists |
US8320998P | 1998-04-27 | 1998-04-27 | |
GBGB9811295.6A GB9811295D0 (en) | 1998-05-26 | 1998-05-26 | Vitronectin receptor antagonists |
US9262298P | 1998-07-13 | 1998-07-13 | |
PCT/US1998/026484 WO1999031061A1 (en) | 1997-12-17 | 1998-12-14 | Integrin receptor antagonists |
Publications (2)
Publication Number | Publication Date |
---|---|
HUP0100397A2 true HUP0100397A2 (hu) | 2001-09-28 |
HUP0100397A3 HUP0100397A3 (en) | 2002-10-28 |
Family
ID=27517453
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HU0100397A HUP0100397A3 (en) | 1997-12-17 | 1998-12-14 | Tetrahydro- or octahydrobenzonaphtyridin and quinolin derivatives, pharmaceutical compositions thereof and process for their preparation |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1040098B1 (hu) |
JP (1) | JP3585839B2 (hu) |
KR (1) | KR20010033248A (hu) |
CN (1) | CN1284944A (hu) |
AT (1) | ATE294163T1 (hu) |
AU (1) | AU739811B2 (hu) |
BG (1) | BG104605A (hu) |
BR (1) | BR9813769A (hu) |
CA (1) | CA2315220C (hu) |
DE (1) | DE69829996T2 (hu) |
EA (1) | EA002822B1 (hu) |
EE (1) | EE200000362A (hu) |
ES (1) | ES2241192T3 (hu) |
GE (1) | GEP20032921B (hu) |
HR (1) | HRP20000401A2 (hu) |
HU (1) | HUP0100397A3 (hu) |
ID (1) | ID24955A (hu) |
IL (1) | IL136495A0 (hu) |
IS (1) | IS5521A (hu) |
NO (1) | NO20003114L (hu) |
NZ (1) | NZ504893A (hu) |
PL (1) | PL341215A1 (hu) |
SK (1) | SK9192000A3 (hu) |
TR (1) | TR200002557T2 (hu) |
WO (1) | WO1999031061A1 (hu) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9805655D0 (en) | 1998-03-16 | 1998-05-13 | Celltech Therapeutics Ltd | Chemical compounds |
US6521626B1 (en) | 1998-03-24 | 2003-02-18 | Celltech R&D Limited | Thiocarboxamide derivatives |
KR20010087125A (ko) * | 1998-04-16 | 2001-09-15 | 데이비드 비. 맥윌리암스 | 인테그린 수용체에 대한 인테그린의 결합을 억제하는 화합물 |
GB9814414D0 (en) | 1998-07-03 | 1998-09-02 | Celltech Therapeutics Ltd | Chemical compounds |
AU748621B2 (en) * | 1998-08-13 | 2002-06-06 | Merck & Co., Inc. | Integrin receptor antagonists |
GB9821061D0 (en) | 1998-09-28 | 1998-11-18 | Celltech Therapeutics Ltd | Chemical compounds |
GB9826174D0 (en) | 1998-11-30 | 1999-01-20 | Celltech Therapeutics Ltd | Chemical compounds |
US6518283B1 (en) | 1999-05-28 | 2003-02-11 | Celltech R&D Limited | Squaric acid derivatives |
BR0011108A (pt) | 1999-06-02 | 2002-03-19 | Merck & Co Inc | Composto, composição farmacêutica, e, processos de eliciar um efeito antagonizante do receptor da integrina, de tratamento ou prevenção da osteoporose, de tratamento ou prevenção de uma condição mediada por antagonismo de um receptor de integrina, de inibição da reabsorção óssea em um mamìfero em necessidade do mesmo, e de tratamento do desenvolvimento tumoral |
US6534513B1 (en) | 1999-09-29 | 2003-03-18 | Celltech R&D Limited | Phenylalkanoic acid derivatives |
JP2003510360A (ja) * | 1999-10-04 | 2003-03-18 | メルク エンド カムパニー インコーポレーテッド | インテグリン受容体拮抗薬 |
WO2001024828A2 (en) * | 1999-10-06 | 2001-04-12 | Basf Aktiengesellschaft | MODULATORS OF CYTOKINE MEDIATED SIGNALLING PATHWAYS AND INTEGRIN αVβ3 RECEPTOR ANTAGONISTS FOR COMBINATION THERAPY |
US6407241B1 (en) | 1999-11-08 | 2002-06-18 | Merck & Co., Inc. | Process and intermediates for the preparation of imidazolidinone αv integrin antagonists |
GB2356630A (en) | 1999-11-10 | 2001-05-30 | Merck & Co Inc | Intermediates used in the preparation of tetrahydronaphthyridine |
ATE258177T1 (de) | 1999-11-23 | 2004-02-15 | Merck & Co Inc | Verfahren für die herstellung und zwischenprodukte von tetrahydro-(1,8)- naphthyridin |
US6455539B2 (en) | 1999-12-23 | 2002-09-24 | Celltech R&D Limited | Squaric acid derivates |
AU780988B2 (en) | 2000-01-24 | 2005-04-28 | Merck & Co., Inc. | Alpha V integrin receptor antagonists |
JP2003531141A (ja) | 2000-04-17 | 2003-10-21 | セルテック アール アンド ディ リミテッド | エナミン誘導体 |
US6403608B1 (en) | 2000-05-30 | 2002-06-11 | Celltech R&D, Ltd. | 3-Substituted isoquinolin-1-yl derivatives |
US6545013B2 (en) | 2000-05-30 | 2003-04-08 | Celltech R&D Limited | 2,7-naphthyridine derivatives |
WO2002004426A1 (en) | 2000-07-07 | 2002-01-17 | Celltech R & D Limited | Squaric acid derivatives containing a bicyclic heteroaromatic ring as integrin antagonists |
WO2002010136A1 (en) | 2000-08-02 | 2002-02-07 | Celltech R & D Limited | 3-substituted isoquinolin-1-yl derivatives |
AU2001290772A1 (en) * | 2000-09-14 | 2002-03-26 | Merck And Co., Inc. | Alpha v integrin receptor antagonists |
US6444680B1 (en) | 2000-11-30 | 2002-09-03 | Merck & Co., Inc. | Amine salts of an integrin receptor antagonist |
US6764842B2 (en) | 2001-03-28 | 2004-07-20 | Merck & Co., Inc. | Enantioselective bioreduction for the preparation of integrin receptor antagonist intermediates |
KR100861466B1 (ko) | 2001-04-24 | 2008-10-02 | 메르크 파텐트 게엠베하 | 항혈관형성제 및 TNFα를 이용한 병용 요법 |
PE20030120A1 (es) * | 2001-06-19 | 2003-02-12 | Merck & Co Inc | Sal amina de un antagonista de receptor de integrin |
US20040224986A1 (en) | 2002-08-16 | 2004-11-11 | Bart De Corte | Piperidinyl targeting compounds that selectively bind integrins |
GB0420424D0 (en) * | 2004-09-14 | 2004-10-20 | Ionix Pharmaceuticals Ltd | Therapeutic compounds |
JP2009523813A (ja) | 2006-01-18 | 2009-06-25 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 癌を治療するためにインテグリンのリガンドを使用する特異的な治療法 |
KR20090108713A (ko) | 2007-01-18 | 2009-10-16 | 메르크 파텐트 게엠베하 | 인테그린 리간드를 사용하는 암치료용 특이적 요법 및 의약 |
WO2009114776A2 (en) | 2008-03-14 | 2009-09-17 | Visen Medical, Inc. | Integrin targeting agents and methods of using same |
NZ597339A (en) | 2009-05-25 | 2013-10-25 | Merck Patent Gmbh | Continuous administration of cilengitide in cancer treatments |
MX2012005994A (es) * | 2009-12-04 | 2012-08-08 | Taisho Pharmaceutical Co Ltd | Compuestos de 2-piridona. |
US8901144B2 (en) | 2013-02-07 | 2014-12-02 | Scifluor Life Sciences, Llc | Fluorinated 3-(2-oxo-3-(3-arylpropyl)imidazolidin-1-yl)-3-arylpropanoic acid derivatives |
CA2899321C (en) * | 2013-02-07 | 2021-03-09 | Ben C. Askew | Fluorinated .alpha..nu.integrin antagonists |
GB201305668D0 (en) | 2013-03-28 | 2013-05-15 | Glaxosmithkline Ip Dev Ltd | Avs6 Integrin Antagonists |
PT3050878T (pt) | 2013-09-24 | 2021-12-02 | Fujifilm Corp | Novo composto contendo azoto ou seu sal, ou seu complexo de metal |
WO2015059668A1 (en) | 2013-10-25 | 2015-04-30 | Novartis Ag | Ring-fused bicyclic pyridyl derivatives as fgfr4 inhibitors |
GB201417002D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compound |
GB201417094D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201417018D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
GB201417011D0 (en) | 2014-09-26 | 2014-11-12 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
CA2976634C (en) | 2015-02-19 | 2023-10-17 | Scifluor Life Sciences, Inc | Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof |
US9802917B2 (en) | 2015-03-25 | 2017-10-31 | Novartis Ag | Particles of N-(5-cyano-4-((2-methoxyethyl)amino)pyridin-2-yl)-7-formyl-6-((4-methyl-2-oxopiperazin-1-yl)methyl)-3,4-dihydro-1,8-naphthyridine-1(2H)-carboxamide |
RU2720989C2 (ru) * | 2015-03-25 | 2020-05-15 | Фуджифилм Корпорэйшн | Способ получения нового азотсодержащего соединения или его соли и получение его промежуточного соединения |
GB201604680D0 (en) | 2016-03-21 | 2016-05-04 | Glaxosmithkline Ip Dev Ltd | Chemical Compounds |
JP2019524702A (ja) * | 2016-07-05 | 2019-09-05 | ザ ロックフェラー ユニバーシティー | テトラヒドロナフチルリジンペンタンアミドインテグリンアンタゴニスト |
WO2018049068A1 (en) | 2016-09-07 | 2018-03-15 | Pliant Therapeutics, Inc. | N-acyl amino acid compounds and methods of use |
PL3660004T3 (pl) | 2016-10-11 | 2023-10-02 | Arvinas Operations, Inc. | Związki i sposoby do ukierunkowanej degradacji receptora androgenowego |
MA47692A (fr) | 2017-02-28 | 2020-01-08 | Morphic Therapeutic Inc | Inhibiteurs de l'intégrine (alpha-v) (bêta-6) |
CA3054604A1 (en) | 2017-02-28 | 2018-09-07 | Morphic Therapeutic, Inc. | Inhibitors of .alpha.v.beta.6 integrin |
CR20200452A (es) * | 2018-03-07 | 2020-11-19 | Pliant Therapeutics Inc | Compuestos de aminoacidos y métodos de uso |
SG11202009734VA (en) * | 2018-04-27 | 2020-11-27 | Arrowhead Pharmaceuticals Inc | Integrin targeting ligands and uses thereof |
TW202010492A (zh) | 2018-06-27 | 2020-03-16 | 美商普萊恩醫療公司 | 具有未分支連接子之胺基酸化合物及使用方法 |
AU2019327475A1 (en) | 2018-08-29 | 2021-03-11 | Morphic Therapeutic, Inc. | INHIBITING αV β6 INTEGRIN |
AR116036A1 (es) * | 2018-08-29 | 2021-03-25 | Morphic Therapeutic Inc | DERIVADOS DE NAFTIRIDINA COMO INHIBIDORES DE INTEGRINA avb6 |
WO2020047207A1 (en) * | 2018-08-29 | 2020-03-05 | Morphic Therapeutics, Inc. | Inhibitors of (alpha-v)(beta-6) integrin |
CA3136745A1 (en) | 2019-04-08 | 2020-10-15 | Pliant Therapeutics, Inc. | Dosage forms and regimens for amino acid compounds |
EP4077309A1 (en) | 2019-12-19 | 2022-10-26 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
CN114507202B (zh) * | 2022-01-26 | 2023-10-03 | 海南大学 | 一种桑辛素类化合物及其制备方法与应用 |
GB202209228D0 (en) | 2022-06-23 | 2022-08-10 | Univ Strathclyde | Modified amino acids and uses thereof |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3843798A (en) * | 1973-03-12 | 1974-10-22 | Stanley Drug Products Inc | Methods and compositions for inducing resistance to bacterial infections |
FR2466252A2 (fr) * | 1979-10-03 | 1981-04-10 | Clin Midy | Nouveaux produits ayant notamment des proprietes anticancereuses a base de chaine a de la ricine et d'une proteine |
US5025025A (en) * | 1989-06-28 | 1991-06-18 | Ciba-Geigy Corporation | (Arylsulfonamido- and pyridyl-)-substituted carboxylic acids and derivatives thereof and use for suppressing thromboxane activity |
FR2658511B1 (fr) * | 1990-02-16 | 1992-06-19 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole et d'azabenzimidazole, antagonistes des recepteurs au thromboxane; leurs procedes de preparation, compositions pharmaceutiques les contenant. |
AU1748792A (en) * | 1991-04-04 | 1992-11-02 | Upjohn Company, The | Phosphorus containing compounds as inhibitors of retroviruses |
US5352667A (en) * | 1991-11-22 | 1994-10-04 | Ofer Lider | Non-peptidic surrogates of the Arg-Gly-Asp sequence and pharmaceutical compositions comprising them |
US5252591A (en) * | 1992-08-14 | 1993-10-12 | G. D. Searle & Company | Pyridinyl-terminated alkylamino ethynyl alanine amino diol compounds for treatment of hypertension |
AU674553B2 (en) * | 1992-10-14 | 1997-01-02 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
NZ277206A (en) * | 1993-12-06 | 1997-11-24 | Cytel Corp | Peptide inhibiting binding of vlh-4 receptor expressed in inflammatory leukocytes and fibronectin cs-1 peptide expressed on endothelial cells involved in inflammatory disease states |
EP0760658B1 (en) * | 1994-05-27 | 2002-11-13 | Merck & Co. Inc. | Compounds for inhibiting osteoclast-mediated bone resorption |
US5650386A (en) * | 1995-03-31 | 1997-07-22 | Emisphere Technologies, Inc. | Compositions for oral delivery of active agents |
PT910563E (pt) * | 1995-06-29 | 2003-09-30 | Smithkline Beecham Corp | Antagonistas de receptores de integrina |
EP0880511A4 (en) * | 1996-01-16 | 1999-06-16 | Merck & Co Inc | INTEGRIN RECEPTOR ANTAGONISTS |
-
1998
- 1998-12-14 DE DE69829996T patent/DE69829996T2/de not_active Expired - Fee Related
- 1998-12-14 TR TR2000/02557T patent/TR200002557T2/xx unknown
- 1998-12-14 KR KR1020007006677A patent/KR20010033248A/ko not_active Application Discontinuation
- 1998-12-14 ES ES98963136T patent/ES2241192T3/es not_active Expired - Lifetime
- 1998-12-14 HU HU0100397A patent/HUP0100397A3/hu unknown
- 1998-12-14 EE EEP200000362A patent/EE200000362A/xx unknown
- 1998-12-14 WO PCT/US1998/026484 patent/WO1999031061A1/en active IP Right Grant
- 1998-12-14 CN CN98813567A patent/CN1284944A/zh active Pending
- 1998-12-14 BR BR9813769-7A patent/BR9813769A/pt not_active IP Right Cessation
- 1998-12-14 AU AU18220/99A patent/AU739811B2/en not_active Ceased
- 1998-12-14 EP EP98963136A patent/EP1040098B1/en not_active Expired - Lifetime
- 1998-12-14 EA EA200000660A patent/EA002822B1/ru not_active IP Right Cessation
- 1998-12-14 NZ NZ504893A patent/NZ504893A/xx unknown
- 1998-12-14 GE GEAP19985463A patent/GEP20032921B/en unknown
- 1998-12-14 AT AT98963136T patent/ATE294163T1/de not_active IP Right Cessation
- 1998-12-14 IL IL13649598A patent/IL136495A0/xx unknown
- 1998-12-14 PL PL98341215A patent/PL341215A1/xx unknown
- 1998-12-14 SK SK919-2000A patent/SK9192000A3/sk unknown
- 1998-12-14 CA CA002315220A patent/CA2315220C/en not_active Expired - Fee Related
- 1998-12-14 JP JP2000538988A patent/JP3585839B2/ja not_active Expired - Fee Related
- 1998-12-14 ID IDW20001164A patent/ID24955A/id unknown
-
2000
- 2000-05-31 IS IS5521A patent/IS5521A/is unknown
- 2000-06-16 NO NO20003114A patent/NO20003114L/no unknown
- 2000-06-16 HR HR20000401A patent/HRP20000401A2/hr not_active Application Discontinuation
- 2000-07-13 BG BG104605A patent/BG104605A/bg unknown
Also Published As
Publication number | Publication date |
---|---|
DE69829996D1 (de) | 2005-06-02 |
ATE294163T1 (de) | 2005-05-15 |
ID24955A (id) | 2000-08-31 |
JP2002508355A (ja) | 2002-03-19 |
HUP0100397A3 (en) | 2002-10-28 |
IL136495A0 (en) | 2001-06-14 |
HRP20000401A2 (en) | 2001-12-31 |
EA200000660A1 (ru) | 2001-02-26 |
EP1040098A4 (en) | 2002-10-30 |
IS5521A (is) | 2000-05-31 |
AU1822099A (en) | 1999-07-05 |
EA002822B1 (ru) | 2002-10-31 |
DE69829996T2 (de) | 2006-02-23 |
CA2315220C (en) | 2006-03-21 |
WO1999031061A1 (en) | 1999-06-24 |
NZ504893A (en) | 2002-10-25 |
SK9192000A3 (en) | 2001-03-12 |
GEP20032921B (en) | 2003-03-25 |
EP1040098A1 (en) | 2000-10-04 |
CA2315220A1 (en) | 1999-06-24 |
NO20003114L (no) | 2000-08-16 |
EP1040098B1 (en) | 2005-04-27 |
BG104605A (bg) | 2001-05-31 |
NO20003114D0 (no) | 2000-06-16 |
KR20010033248A (ko) | 2001-04-25 |
JP3585839B2 (ja) | 2004-11-04 |
CN1284944A (zh) | 2001-02-21 |
TR200002557T2 (tr) | 2000-12-21 |
BR9813769A (pt) | 2000-10-10 |
AU739811B2 (en) | 2001-10-18 |
EE200000362A (et) | 2001-12-17 |
ES2241192T3 (es) | 2005-10-16 |
PL341215A1 (en) | 2001-03-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUP0100397A2 (hu) | Tetrahidro- vagy oktahidrobenzo-naftiridin és kinolinszármazékok, ezeket tartalmazó gyógyszerkészítmények és eljárás előállításukra | |
HUP0105409A2 (hu) | Csípőbél-epesav transzport és taurokolát felvétel inhibitor aktivitású 1,2-benzotiazepin-származékok, alkalmazásuk és az ezeket tartalmazó gyógyszerkészítmények | |
SE9902987D0 (sv) | Novel compounds | |
SE9904738D0 (sv) | Novel compounds | |
HUP0104188A2 (hu) | Antranilsav- és tioantranilsav-N-aril-amidok, előállításuk és alkalmazásuk VEGF receptor tirozinkináz inhibítorokként | |
HUP9903671A2 (hu) | Gonadotropint leadó hormonok antagonistái,e vegyületeket tartalmazó gyógyászati készítmények,valamint azok előállítása | |
HUT67434A (en) | Fluoroalkoxy-benzylamino derivatives of nitrogen containing heterocycles and pharmaceutical compositions containing them and process for their production | |
HUP9902121A2 (hu) | Gonadotropin-leadó hormon antagonista hatású indolszármazékok és ezeket a vegyületeket tartalmazó gyógyszerkészítmények | |
DK0790986T3 (da) | Anilinderivater | |
NO20053827L (no) | Nye forbindelser. | |
HUP9901960A2 (hu) | Kristályos ziprasidont tartalmazó gyógyszerkészítmények és eljárás ilyen kristályok előállítására | |
FI941987A (fi) | Uudet aminohappojohdannaiset, menetelmät niiden valmistamiseksi ja näitä yhdisteitä sisältävät farmaseuttiset koostumukset | |
DE60214179D1 (de) | IMIDAZOi1,2-AöPYRIDIN-DERIVATE ZUR PROPHYLAXE UND BEHANDLUNG VON HERPES-INFEKTIONEN | |
HUP0401009A2 (hu) | 5-Hidroxitriptamin-6-ligandumokként alkalmazható 1-aril- vagy 1- alkil-szulfonilbenzazol-származékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
FI875229A (fi) | Menetelmä uusien farmakologisesti aktiivisten katekolijohdoksien valmistamiseksi | |
HUP0401333A2 (hu) | Spiropirazol vegyületek és ezeket tartalmazó gyógyszerkészítmények | |
HUP0402227A2 (hu) | Fenil-szubsztituált triazolok és az AKL5 kináz szelektív inhibitoraiként történő felhasználásuk és a vegyületeket tartalmazó gyógyszerkészítmények | |
DZ1694A1 (fr) | "n-(2-Aminoethyl)-benzothialozones". | |
HU911301D0 (en) | Process for producing 2,9-disubstituted 4h-pyrido(1,2a)-pyrimidine derivatives and pharmaceutical preparatives containing these compounds as active substance | |
DE69911935D1 (de) | Granulatimide-derivate zur behandlung von krebs | |
DE69330282D1 (de) | Chinolon und acridinon derivate zur behandlung der harninkontinenz | |
HUP0400156A2 (hu) | Pirrolidinszármazékok, mint Xa faktor inhibítorok, előállításuk és ezeket tartalmazó gyógyszerkészítmények | |
GR1001597B (el) | Νέα βιολογικώς δραστικά παράγωγα εμπουρναμενίνης, φαρμακευτικές συν?έσεις οι οποίες περιέχουν αυτά και μέ?οδος δια την παρασκευή αυτών. | |
KR950014103A (ko) | 1-[2H-1-벤조피란-2-온-8-일]-피페라진 유도체(1-[2H-1-benzopyran-2-one-8-yl]-piperazine derivatives) | |
NO179974C (no) | Analogifremgangsmåte for fremstilling av terapeutisk aktive piperidinforbindelser |